Memory and motivation in human health and disease
In plain English
AI plain-English summaryApathy and short-term memory loss are not separate symptoms but measurable brain network failures that could be treated with the same drugs, regardless of which disease caused them. Current treatments for brain diseases target specific diagnoses—Alzheimer’s, Parkinson’s, stroke—but the same cognitive or behavioural syndrome often appears across these conditions. This project tests a different approach: instead of treating the disease label, treat the syndrome. The researchers will first break down apathy and memory deficits into their precise behavioural components, then use brain scans to identify the neural networks that produce each component. They will look for these network signatures in patients with four different brain diseases, and also in people at high risk of developing neurodegeneration but who show no symptoms yet. If this succeeds, it could reshape how neurologists prescribe drugs. A patient with apathy after a stroke might receive the same cholinergic medication as a patient with apathy from Parkinson’s, because both share the same disrupted network. It could also allow early detection of network dysfunction years before a diagnosis, opening a window for preventive treatment. This is fundamental science about how brain systems generate behaviour, but it has a direct clinical target: replacing trial-and-error prescribing with network-based precision medicine.
View original technical description
View the original record at the funder ↗
Researchers
Related Research
Grants with similar aims, by meaning.
Original classification
Principal Research Fellowship RenewalPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know